Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M95.7Revenue $M102Net Margin (%)-104.5Altman Z-Score-3.7
Enterprise Value $M78.9EPS $-1.0Operating Margin %-72.1Piotroski F-Score1
P/E(ttm)--Beneish M-Score-3.7Pre-tax Margin (%)-104.4Higher ROA y-yN
Price/Book18.410-y EBITDA Growth Rate %--Quick Ratio4.6Cash flow > EarningsY
Price/Sales0.95-y EBITDA Growth Rate %1.8Current Ratio4.8Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-188.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M104ROIC % (ttm)-2,721.0Gross Margin Increase y-yN

Gurus Latest Trades with VVUS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VVUSFirst Eagle Investment 2013-06-30 Sold Out -0.01%$10.43 - $15.1
($12.91)
$ 0.93-93%Sold Out0
VVUSFirst Eagle Investment 2013-03-31 Buy 0.01%$10.2 - $14.87
($12.43)
$ 0.93-93%New holding200,000
VVUSGeorge Soros 2012-09-30 Sold Out -0.06%$17.81 - $29.93
($23.45)
$ 0.93-96%Sold Out0
VVUSGeorge Soros 2012-06-30 Reduce-0.09%$21.5 - $28.68
($24.02)
$ 0.93-96%Reduce -64.93%150,000
VVUSGeorge Soros 2012-03-31 Buy 0.14%$9.99 - $23.78
($14.83)
$ 0.93-94%New holding427,750
VVUSGeorge Soros 2011-03-31 Sold Out $6.06 - $11.2
($7.95)
$ 0.93-88%Sold Out0
VVUSGeorge Soros 2010-12-31 Buy $5.94 - $9.78
($7.38)
$ 0.93-87%New holding19,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VVUS is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


VVUS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Varghese Santosh TVP, Medical & Reg Affairs 2015-07-01Sell7,899$2.32-59.91view
Slebir John LSVP, Business Development & GC 2015-07-01Sell9,215$2.32-59.91view
Day WesleyVP, Clinical Development 2015-07-01Sell7,881$2.32-59.91view
Day WesleyVP, Clinical Development 2015-01-29Sell472$2.78-66.55view
Slebir John LSVP, Business Development & GC 2015-01-29Sell630$2.78-66.55view
MARSH GUY PVP, US Operations & GM 2015-01-29Sell238$2.78-66.55view
Sanford Svai SCFO & Chief Accounting Officer 2015-01-29Sell472$2.78-66.55view
NORTH TIDE CAPITAL, LLC10% Owner 2015-01-08Buy500,000$3.12-70.19view
NORTH TIDE CAPITAL, LLC10% Owner 2015-01-06Buy476,800$3.04-69.41view
NORTH TIDE CAPITAL, LLC10% Owner 2015-01-02Buy523,200$2.9-67.93view

Quarterly/Annual Reports about VVUS:

    News about VVUS:

    Articles On GuruFocus.com
    Biotech Momentum Indicators: Achaogen (AKAO), Novartis (NVS), VIVUS (VVUS) Apr 01 2015 
    5-year lows: PICO Holdings Inc, Black Box Corp, Vivus, and Electro Rent Corp. Mar 29 2015 
    A Look at Pharma Company Dermira's Performance Mar 27 2015 
    5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp. Feb 08 2015 
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    Weekly Three-Year Low Highlight: VVUS, RALY, WILN, COVS Mar 25 2014 
    Billionaires Hold Four Stocks, 59% Off Sep 30 2013 
    Unique Investor Kyle Bass Unloads Five May 29 2013 
    Weekly Guru Bargains Highlights: FTE, VVUS, PAY, TIBX, VMW Feb 24 2013 
    Weekly Guru Bargains Highlights: FTNT, VVUS, HAE, PC, TIBX Dec 09 2012 

    More From Other Websites
    VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 28 2016
    The Zacks Analyst Blog Highlights: Gilead, MannKind, VIVUS and Baxalta Jan 07 2016
    Biotech Stock Roundup: MannKind Tanks on Deal Termination, Speedy Review for Gilead Drug Jan 06 2016
    VIVUS to Regain U.S. and Canada Stendra Rights from Endo Jan 04 2016
    VIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD... Dec 31 2015
    VIVUS, Inc. Announces Intent to Reacquire U.S. and Canadian Rights for Stendra(R) (Avanafil) Dec 31 2015
    A New Take On New Year's And Chronic Weight Management: Smart Changes™ Program Combines Positive... Dec 29 2015
    VIVUS, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 23 2015
    VIVUS INC Financials Dec 08 2015
    Should You Buy VIVUS, Inc. (VVUS)? Nov 30 2015
    Should You Buy Bravo Brio Restaurant Group, Inc. (BBRG)? Nov 29 2015
    Drugmakers drop weight Nov 25 2015
    VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 24 2015
    Trading Ahead of Upcoming Developments - Research on Vivus, ReneSola, Consumer Portfolio Services... Nov 23 2015
    VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 09 2015
    VIVUS' (VVUS) Q3 Loss Grows Y/Y, Revenues Top Estimates Nov 05 2015
    Edited Transcript of VVUS earnings conference call or presentation 4-Nov-15 9:30pm GMT Nov 04 2015
    Vivus reports 3Q loss Nov 04 2015
    Vivus reports 3Q loss Nov 04 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK